Thousands of patients with multiple sclerosis (MS) in England are to become the first in Europe to benefit from a major roll out of an immunotherapy pill.
Current treatments involve regular trips to hospital, drug infusions, frequent injections and extensive monitoring, which add to the burden on patients and healthcare systems.